“…Drugs: (i) The universal 5-HT receptor agonist, 5-hydroxytryptamine hydrochloride, acting potently at 5-HT 2A and 5-HT 2B receptors (Doyle et al, 1986; Misane and Ogren, 2000; Li et al, 2010), as well as at 5-HT 6 and 5-HT 7 receptors but less potently at 5-HT 1 receptors (Granados-Soto et al, 2010); 5-HT 3 (Chetty et al, 2006), 5-HT 4 (Prins et al, 2000), 5-HT 5 (Thomas et al, 2000; Nelson, 2004), and 5-HT 6 (Monsma et al, 1993) receptors; (ii) fluoxetine hydrochloride and paroxetine hydrochloride (from Sigma-Aldrich, St. Louis, MO, USA), subtype-specific, almost equipotent agonists at the astrocytic 5-HT 2B receptor; (iii) methiothepin maleate (1-[10,11-dihydro-8-(methyl-thio)dibenzo( Z )[ b,f ]thiepin-10-yl]-4-methylpiperazine maleate), from Research Biochemicals, Inc, a non-specific antagonist of all 5-HT receptors, except 5-HT 3 and 5-HT 4 (Misane and Ogren, 2000), which has high affinity for 5-HT 2A (Briejer et al, 1997) and 5-HT 2B receptors (Glusa and Pertz, 2000), 5-HT 5 receptors (Thomas et al, 2000), 5-HT 6 receptors (Misane and Ogren, 2000) and 5-HT 7 receptors (Jänichen et al, 2005), but lower affinity for at least some of the 5-HT 1 receptors (Misane and Ogren, 2000); (iv) the selective 5-HT 2B/C receptor antagonist SB221284 (2,3-dihydro-5-(methylthio)- N -3-pyridinyl-6-(trifluoromethyl)-1 H -indole-1-carboxamide), from Tocris Cookson Ltd. UK. All drugs were prepared in sterile physiological saline (154 mM NaCl).…”